2005PubMedRequires access

Development of rabies DNA vaccine using a recombinant plasmid.

Nishant Rai, P. Kaushik, A. Rai

Open publisher page 13 citations

Abstract

A recombinant plasmid pTargeT.rabgp containing the glycoprotein (G) gene of Rabies virus (RV) was constructed and produced for immunogenicity studies on mice and dogs. The mice immunized twice with 50 microg or 100 microg of pTargeT.rabgp intramuscularly (i.m.), showed a serum antibody titer of 256 or 64, respectively 14 days post immunization (p.i.). When the vaccinated mice were challenged at 14 days p.i. with RV i.c., they were protected in 81.25% or 87.5%, respectively. A positive cell mediated immune response was observed by lymphocyte proliferation assay and macrophage migration inhibition test. These results indicate that the pTargeT.rabgp plasmid can be used as a rabies DNA vaccine.

About this research paper

What this paper is about

A recombinant plasmid pTargeT.rabgp containing the glycoprotein (G) gene of Rabies virus (RV) was constructed and produced for immunogenicity studies on mice and dogs. The mice immunized twice with 50 microg or 100 microg of pTargeT.rabgp intramuscularly (i.m.), showed a serum antibody titer of 256 or 64, respectively 14 days post immunization (p.i.). When the vaccinated mice were challenged at 14 days p.i. with RV i.c., they were protected in 81.25% or 87.5%, respectively. A positive cell mediated immune response was observed by lymphocyte proliferation assay and macrophage migration inhibition test. These results indicate that the pTargeT.rabgp plasmid can be used as a rabies DNA vaccine.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A recombinant plasmid pTargeT.rabgp containing the glycoprotein (G) gene of Rabies virus (RV) was constructed and produced for immunogenicity studies on mice and dogs. The mice immunized twice with 50 microg or 100 microg of pTargeT.rabgp intramuscularly (i.m.), showed a serum antibody titer of 256 or 64, respectively 14 days post immunization (p.i.). When the vaccinated mice were challenged at 14 days p.i. with RV i.c., they were protected in 81.25% or 87.5%, respectively. A positive cell mediated immune response was observed by lymphocyte proliferation assay and macrophage migration inhibition test. These results indicate that the pTargeT.rabgp plasmid can be used as a rabies DNA vaccine.

Key concepts: Immunogenicity, DNA vaccination, Virology, Recombinant DNA, Rabies, Rabies virus, Titer, Plasmid

Related papers

Back to paper searchBrowse research topicsOriginal source
Development of rabies DNA vaccine using a recombinant plasmid. — Research Paper | ScholarLens